Navigation Links
PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
Date:11/23/2011

al results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, politic
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
2. UCB and PAREXEL Sign Strategic Partnership Agreement
3. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
4. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
5. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
6. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
7. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
8. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
9. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
10. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
11. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015   ndd Medical Technologies ... (PFT) that employs precise ultrasound technology, announced that its ... held by the San Antonio Pulmonary Fibrosis Support Group. ... or pulmonary fibrosis (PF), as well as those suspected ... footprint of a mere 12 square inches, EasyOne Pro ...
(Date:3/5/2015)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, today announced the appointment of several ... panel of experts will provide support for planning ... the company pipeline of novel investigational therapies to ... range of areas including opioid receptors, addiction, psychiatry, ...
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, Inc. ... that it has acquired the approved abbreviated new ... 50mg, 100mg and 150mg, previously marketed by Teva ... for this product was approximately $39 million in ... , President and CEO of ANI Pharmaceuticals, stated, ...
Breaking Medicine Technology:ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... Phase III data shows significant antitumor benefit in patients ... Early data show that at eight weeks of treatment, ... patients with advanced liver cancer - New data ... better cognitive function than those taking tamoxifen - ...
... May 27 Researchers have discovered a novel molecular path ... , a disease that mainly affects women and slowly ... finding, significant because it is a first step toward developing ... the June 11, 2009, issue of the New ...
Cached Medicine Technology:Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 2Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 3Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 4Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 5Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 6Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 7Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 8Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 9Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 10Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 11Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 12Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 13Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 14Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 15Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 16Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 17Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 18Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 2Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 3Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 4
(Date:3/6/2015)... As the Mayo Clinic's 2012 published ... & Associates Nationwide Legal Services, A.P.C., comments on these ... Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in ... “In light of a recently filed lawsuit, Ford & ... and explore the Mayo Clinic's Benicar case study findings ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as host to ... include the following activities:, October 5: ... 6: Conference Day 1, ending with a Fashion Show and ... with Local Entertainment and Dinner , October 8: ... , October 9-10: Textiles in India Tour (optional; ...
(Date:3/5/2015)... (PRWEB) March 06, 2015 The global digital PCR ... 2019, at CAGR of 7.8% from 2014 to 2019. , The ... at a CAGR of 7.8% from 2014 to 2019. Although the ... larger shares in the digital PCR (dPCR) and qPCR market the ... 10.7% in the forecast period. The growth of the digital PCR ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... dangerous levels of formaldehyde in low-cost laminate ... Bamboo, the leading manufacturer of eco-friendly building materials ... to customer safety by testing all their flooring ... leading emissions detection laboratory Benchmark International ...
(Date:3/5/2015)... FL (PRWEB) March 05, 2015 ... company focused on the peripheral nerve repair market, reported ... ended December 31, 2014 compared to $2.98 million in ... of its growth strategies. , “Our strong fourth ... our peripheral nerve repair products which is driving increased ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... the past decade, Asia has been the preferred destination ... medical treatments. The increase is partially due to high ... and United Kingdom. Specialized treatments, surgeries and therapies are ... cost, yet with bigger perks when it comes to ...
... Amber Court ( http://www.AmberCourtAL.com ) reaffirms its ... Public Advocate Ronald K. Chen,s investigation of Wisconsin-based Assisted ... depleted their personal savings. , ... of Amber Court Assisted Living ...
... April 21 When Gundersen Lutheran Health System set out ... to 2 percent decrease that,s common at healthcare facilities. Instead, ... less than two years. That,s 9,600 metric tons of carbon ... equivalent of removing 1,631 cars from the road. The La ...
... receive Magnet re-designation.DALLAS, April 21 The American ... Baylor University Medical Center at Dallas (Baylor ... effective immediately. Fewer than six percent of hospitals ... and merely two percent of the nation,s hospitals ...
... (BRONX, NY) Recurrent and metastatic endometrial and ... have spread to other organs and typically have developed ... chemotherapy may not be able to endure more chemo. ... Yeshiva University have shown that a combination of two ...
... Blue Cross and Blue Shield of Minnesota and ... financial results for 2008. The organization reported an overall ... revenues of $8.8 billion, with $8.0 billion paid to ... deficit was the result of net realized capital losses ...
Cached Medicine News:Health News:Medical Tourism is Good Therapy for the Hotel Industry 2Health News:Medical Tourism is Good Therapy for the Hotel Industry 3Health News:Medical Tourism is Good Therapy for the Hotel Industry 4Health News:Medical Tourism is Good Therapy for the Hotel Industry 5Health News:Amber Court Assisted Living Communities Reaffirms its Commitment to Seniors on Medicaid 2Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Blue Cross and Blue Shield of Minnesota Releases 2008 Financial Results 2
... The Finnpipette Digital offers improved ... The rounded handle, modified grippy finger ... enhance operator comfort and efficiency. Finnpipette ... with power-boosted gearing mechanism (pat. pend.) ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases....
Medicine Products: